INTRODUCTION

Papillary thyroid carcinoma (PTC) is the most common malignancy of the thyroid. It has a good prognosis due to its slow growth and less invasive behavior [1]. However, lymph node (LN) metastasis or aggressive behavior, such as local invasion and distant metastasis are seen in some cases of PTC. Cervical LN metastasis is common in PTC; it is associated with recurrence and is a prognostic factor in older patients [2,3].

Microscopic examination of metastatic LNs can establish whether tumor foci are located within LNs with intact nodal capsules, or extend into the surrounding perinodal fat tissue beyond the fibrous capsules of the LNs. In patients with head and neck squamous cell carcinoma, extracapsular spread (ECS) is associated with aggressive tumor behavior, and is regarded as a major risk factor for local recurrence [4,5]. However, ECS of metastatic lymph nodes has not been well established in well-differentiated thyroid carcinoma.

We hypothesized that ECS of metastatic LN may affect the prognosis of PTC. The purpose of this study was therefore to determine the clinical significance of ECS of metastatic LN in PTC.

MATERIALS AND METHODS

We retrospectively reviewed the data of 722 patients who underwent thyroidectomy for the treatment of PTC from April 2001 to November 2009. We confined this study to patients who under-
went total thyroidectomy and LN dissection including central or lateral neck dissection. We excluded patients who did not receive neck dissection or total thyroidectomy, and had distant metastasis before operation, as well as recurrent cases. Finally, 335 patients were enrolled. The study was approved by the Institutional Review Board of Hanyang University Hospital (HYUH 2013-12-008-003).

Preoperative imaging was performed by neck ultrasonography (US) and computed tomography (CT), and in some cases, fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography ($^{18}$FDG-PET/CT).

We analyzed various clinicopathologic characteristics, the size and number of metastatic foci, and ECS in metastatic LNs. Pathologic review was undertaken by two expert pathologists in our institution. Tumor size was defined by the length of the long axis of the largest nodule, and ECS by the existence of tumor foci that extended into the perinodal fat tissue surrounding the fibrous capsule of the LN (Fig. 1). Positive ECS patients were those who had ECS of one or more LNs.

Clinically positive LN was defined as LN detected by palpation or preoperative image study such as US, CT, or $^{18}$FDG-PET/CT. We did not perform prophylactic neck dissection in the lateral compartment. We only performed therapeutic lateral compartment neck dissection when LN metastasis was suspicious clinically or LN metastasis was confirmed by US-guided fine needle aspiration cytology.

Tumors were classified according to 7th edition of the American Joint Committee on Cancer (AJCC) Staging System [6]. Local recurrence was evaluated every 6–12 months by neck US, radioactive iodine scan and stimulated serum thyroglobulin levels. Statistical analysis was performed using IBM SPSS ver. 21.0 (IBM Co., Armonk, NY, USA). Pearson chi-square test, Fisher exact test, or the independent $t$-test was used in evaluating the relation between local recurrence and various clinical factors, as well as between ECS and various clinical factors. After identifying significant clinical factors, a multiple regression analysis was performed to identify risk factors related to local recurrence and ECS.

RESULTS

The mean age of the 335 patients was 46.9 (standard deviation, ±13.1) years, and 80.6% were female. Pathologic cervical LN metastasis was found in 201 patients (56.6%). According to the AJCC staging system, the numbers of patients in stages I, II, III, and IV were 185 (55.2%), 9 (2.7%), 101 (30.1%), and 40 (11.7%), respectively. Postoperative radioactive iodine ablation was performed in 306 patients (91.3%), and the mean follow-up period was 69.0 months (range, 33 to 147 months). Factors related to LN metastasis are listed in Table 1. Cervical LN metastasis was related to age, gender, and tumor size ($P=0.008$, $P=0.030$, and $P<0.001$, respectively).

Of 201 patients with cervical LN metastasis, the proportions of LNs that were detected by preoperative physical examination or imaging were 13.7% (20/146) and 100% (55/55) in central and lateral compartment, respectively. A comparison between the clinically positive and the clinically negative LN groups is shown in Table 2. Metastatic LN detected clinically was related to metastatic LN size ($P=0.001$).
### Table 1. Factors related to cervical lymph nodes metastasis in papillary thyroid carcinoma

| Variable                        | No cervical node metastasis (n=134) | Cervical node metastasis (n=201) | Univariate analysis (P-value) | Multivariate analysis (P-value) |
|---------------------------------|-------------------------------------|----------------------------------|--------------------------------|---------------------------------|
| Age (year)                      | 49.6±12.7                           | 45.1±13.1                        | 0.002*                         | 0.008†                          |
| Gender (female:male)            | 6.9:1                               | 3.2:1                            | 0.016‡                         | 0.030‡                          |
| Tumor size (mm)                 | 11.6±8.2                            | 18.0±11.3                        | <0.001*                        | <0.001†                         |
| Tumor multiplicity              | 28 (20.9)                           | 62 (30.8)                        | 0.059†                         | -                               |
| Tumor bilaterality              | 23 (17.2)                           | 47 (23.4)                        | 0.217‡                         | -                               |
| Extrathyroidal extension        | 43 (32.1)                           | 86 (42.8)                        | 0.052‡                         | -                               |
| T classification                |                                     |                                  |                                |                                 |
| T1                               | 75 (56.0)                           | 77 (38.3)                        |                                |                                 |
| T2                               | 15 (11.2)                           | 34 (16.9)                        |                                |                                 |
| T3                               | 43 (32.1)                           | 82 (40.6)                        |                                |                                 |
| T4                               | 1 (0.7)                             | 8 (4.0)                          |                                |                                 |
| N classification                |                                     |                                  |                                |                                 |
| N0                               | 134 (100)                           | 0 (0)                            |                                |                                 |
| N1a                              | 0 (0)                               | 146 (72.6)                       |                                |                                 |
| N1b                              | 0 (0)                               | 55 (27.4)                        |                                |                                 |
| Stage                            |                                     |                                  |                                |                                 |
| I                                | 96 (71.6)                           | 89 (44.3)                        |                                |                                 |
| II                               | 6 (4.5)                             | 3 (1.5)                          |                                |                                 |
| III                              | 31 (23.1)                           | 70 (34.8)                        |                                |                                 |
| IV                               | 1 (0.7)                             | 39 (19.4)                        |                                |                                 |

Values are presented as mean±standard deviation or number (%).

*Student t-test. †Chi-square test. ‡Multiple regression analysis.

### Table 2. Factors related to clinically detected lymph node metastasis

| Variable                        | Clinically negative node (n=126) | Clinically positive node (n=75) | Univariate analysis (P-value) | Multivariate analysis (P-value) |
|---------------------------------|----------------------------------|---------------------------------|--------------------------------|---------------------------------|
| Age (year)                      | 45.3±12.3                        | 44.7±14.4                       | 0.748*                         |                                |
| Male sex                        | 22 (17.5)                        | 26 (34.7)                       | 0.007†                         | 0.328‡                          |
| Tumor size (mm)                 | 16.5±9.7                         | 20.7±13.3                       | 0.019†                         | 0.284‡                          |
| Tumor multiplicity              | 40 (31.7)                        | 22 (29.3)                       | 0.754†                         | -                               |
| Tumor bilaterality              | 34 (27.0)                        | 13 (17.3)                       | 0.125‡                         | -                               |
| Extrathyroidal extension        | 39 (31.0)                        | 47 (62.7)                       | <0.001*                        | 0.345‡                          |
| Lymph node size (mm)            | 4.9±3.3                          | 14.7±8.2                        | <0.001*                        | 0.001†                          |
| Metastatic foci size (mm)       | 2.9±2.8                          | 11.7±8.2                        | <0.001*                        | 0.415‡                          |
| Multiplicity of metastatic foci | 66 (52.4)                        | 63 (84.0)                       | <0.001*                        | 0.301‡                          |
| Extracapsular spread            | 20 (15.9)                        | 44 (58.7)                       | <0.001*                        | 0.058‡                          |

Values are presented as mean±standard deviation or number (%).

*Student t-test. †Chi-square test. ‡Multiple regression analysis.

### Table 3. Factors related to extracapsular spread (ECS) of metastatic lymph nodes in papillary thyroid carcinoma

| Variable                        | Lymph node metastasis with ECS (n=64) | Lymph node metastasis without ECS (n=137) | Univariate analysis (P-value) | Multivariate analysis (P-value) |
|---------------------------------|--------------------------------------|-------------------------------------------|--------------------------------|---------------------------------|
| Age (year)                      | 42.9±14.0                           | 46.1±12.6                                 | 0.104*                         |                                |
| Male sex                        | 24 (37.5)                           | 24 (17.5)                                 | 0.003†                         | 0.045‡                          |
| Tumor size (mm)                 | 22.1±12.6                           | 16.1±10.1                                 | <0.001*                        | 0.003‡                          |
| Tumor multiplicity              | 25 (39.1)                           | 37 (27.0)                                 | 0.102†                         | -                               |
| Tumor bilaterality              | 19 (29.7)                           | 28 (20.4)                                 | 0.157‡                         | -                               |
| Extrathyroidal extension        | 43 (67.2)                           | 43 (31.4)                                 | <0.001†                        | <0.001†                         |

Values are presented as mean±standard deviation or number (%).

*Student t-test. †Chi-square test. ‡Multiple regression analysis.
Pathologic review of the 201 patients with cervical LN metastasis showed that 64 (31.8%) had ECS. Positive ECS was significantly related to male gender, tumor size, and extrathyroidal extension (ETE) (Table 3).

ECS was found in 242 of the total of 1,121 LNs (21.6%) removed in all patients. It was seen in 11.0% (49/445) and 28.6%

### Table 4. Factors related with to spread in metastatic lymph nodes

| Variable                  | With ECS | Without ECS | Univariate analysis (P-value) | Multivariate analysis (P-value) |
|---------------------------|----------|-------------|-------------------------------|--------------------------------|
| Total metastatic LN       | 242      | 879         |                               |                                |
| LN size (mm)              | 8.7 ± 5.5| 6.0 ± 5.1   | <0.001*                       | <0.001*                        |
| Foci size (mm)            | 7.6 ± 5.3| 3.7 ± 4.5   | <0.001*                       | <0.001*                        |
| Foci multiplicity         | 111 (45.9)| 381 (43.3)  | 0.511†                        |                                |
| Central metastasis group  | 49       | 396         |                               |                                |
| LN size (mm)              | 5.7 ± 4.3| 4.0 ± 2.5   | <0.001*                       |                                |
| Foci size (mm)            | 4.5 ± 3.6| 2.0 ± 1.9   | <0.001*                       | <0.001*                        |
| Foci multiplicity         | 23 (46.9)| 162 (40.9)  | 0.445†                        |                                |
| Lateral metastasis group  | 193      | 483         |                               |                                |
| LN size (mm)              | 9.5 ± 5.6| 7.6 ± 6.0   | <0.001*                       |                                |
| Foci size (mm)            | 8.4 ± 5.4| 5.1 ± 5.4   | <0.001*                       | <0.001*                        |
| Foci multiplicity         | 88 (45.6)| 219 (45.3)  | >0.999†                       |                                |

Values are presented as mean ± standard deviation or number (%).

ECS, extracapsular spread; LN, lymph node.

*Student t-test. †Chi-square test. ‡Multiple regression analysis.

### Table 5. Factors related to loco-regional recurrence in papillary thyroid carcinoma

| Variable                  | Recurrence (n=13) | No recurrence (n=322) | Univariate analysis (P-value) | Multivariate analysis (P-value) |
|---------------------------|-------------------|-----------------------|-------------------------------|--------------------------------|
| Age (year)                | 38.2 ± 7.9        | 47.2 ± 13.2           | 0.014*                        | 0.029†                          |
| Male sex                  | 6 (46.2)          | 59 (18.3)             | 0.024†                        | 0.063‡                          |
| Tumor size (mm)           | 18.5 ± 9.9        | 15.3 ± 10.7           | 0.300*                        |                                |
| Tumor multiplicity        | 8 (61.5)          | 82 (25.5)             | 0.008†                        | 0.499†                          |
| Tumor bilaterality        | 7 (53.8)          | 63 (19.6)             | 0.008†                        | 0.555†                          |
| Extrathyroidal extension  | 10 (76.9)         | 119 (37.0)            | 0.006†                        | 0.031†                          |
| CCLN metastasis           | 5 (38.5)          | 141 (43.8)            | 0.782‡                        |                                |
| LCLN metastasis           | 6 (46.2)          | 49 (15.2)             | 0.010†                        | 0.042‡                          |
| LN metastasis             | 11 (84.6)         | 190 (59.0)            | 0.084†                        |                                |
| Metastatic LN size (mm)   | 15.2 ± 7.1        | 8.2 ± 7.2             | 0.002*                        | 0.630                           |
| Metastatic Foci size (mm) | 13.7 ± 7.7        | 5.7 ± 6.7             | <0.001*                       | 0.095                           |
| Extracapsular spread      | 11 (84.6)         | 53 (27.9)             | <0.001*                       | 0.002†                          |

Values are presented as mean ± standard deviation or number (%).

CCLN, central compartment lymph node; LCLN, lateral compartment lymph node; LN, lymph node.

*Student t-test. †Chi-square test. ‡Multiple regression analysis.

### Table 6. Factors related to loco-regional recurrence in papillary thyroid carcinoma with lymph node metastasis

| Variable                  | Recurrence (n=13) | No recurrence (n=322) | Univariate analysis (P-value) | Multivariate analysis (P-value) |
|---------------------------|-------------------|-----------------------|-------------------------------|--------------------------------|
| Age (year)                | 36.5 ± 7.1        | 45.6 ± 13.2           | 0.025*                        | 0.024†                          |
| Male sex                  | 6 (54.5)          | 42 (22.1)             | 0.024†                        | 0.084‡                          |
| Tumor size (mm)           | 19.3 ± 10.2       | 18.0 ± 11.4           | 0.708*                        |                                |
| Tumor multiplicity        | 7 (63.6)          | 55 (28.9)             | 0.022‡                        | 0.671†                          |
| Tumor bilaterality        | 6 (54.5)          | 41 (21.6)             | 0.022‡                        | 0.319‡                          |
| Extrathyroidal extension  | 10 (90.9)         | 76 (40.0)             | 0.001‡                        | 0.106†                          |
| Lymph node size (mm)      | 15.2 ± 7.1        | 8.2 ± 7.2             | 0.002*                        | 0.337†                          |
| Metastatic foci size (mm) | 13.7 ± 7.7        | 5.7 ± 6.7             | <0.001*                       | 0.285‡                          |
| Multiplicity of metastatic foci | 11 (100)      | 118 (62.1)            | 0.019†                        | 0.275‡                          |
| Extracapsular spread      | 11 (100)          | 53 (27.9)             | <0.001*                       | 0.007†                          |

Values are presented as mean ± standard deviation or number (%).

*Student t-test. †Chi-square test. ‡Multiple regression analysis.
Several studies have concluded that ECS of metastatic LNs is related with loco-regional recurrence. In this study, the size of metastatic LNs was not significantly correlated with local recurrence although this is controversial [11,15,16]. The size and number of metastatic LNs is thought to be associated with ECS of metastatic LNs [22,23]. In our study, ECS of metastatic LNs was significantly associated with lower age, large tumor size, presence of ECS, and size and number of metastatic LNs [11,12,17-21]. T4 tumors and high-risk features according to the American Thyroid Association guidelines were associated with ECS of metastatic LNs [19]. In this study, ECS of metastatic LNs was related to male gender, large tumor size, presence of ETE, large size of metastatic LNs and large size of metastatic foci.

ECS of metastatic LNs is regarded as a poor prognostic factor for local recurrence and survival in some human cancers such as head and neck, breast and bladder cancers. ECS of metastatic LNs, especially in head and neck cancers, is considered an important adverse prognostic factor for local recurrence and distant metastasis, as well as for survival [4,5].

There are differing opinions about the significance of ECS in PTC. Several studies have reported it to be a prognostic indicator for local recurrence, distant metastasis, and decreased survival [11,12,17-21]. A recent paper concluded that the risk of recurrence was 1% in patients with LN metastasis without ECS, 4% in those with three metastatic LNs showing ECS, and 32% in those with more than three metastatic LNs showing ECS [11]. According to another study more than three metastatic LNs showing ECS was also a significant risk factor for persistent disease and recurrent disease [20]. In addition, concurrent BRAF V600E mutation and ECS of metastatic LNs have been shown to predict significantly worse disease free survival [18]. However, in other studies workers found that recurrence was not correlated with ECS of metastatic LNs [22,23].

In our study, ECS of metastatic LNs was significantly associated with loco-regional recurrence. Young age and presence of ECS, in particular, were significantly associated with recurrence among patients with cervical LN metastasis. Therefore, close postoperative surveillance and appropriate adjuvant treatment should be considered in patients with ECS in order to detect early recurrence and minimize loco-regional recurrence. In this study, only two patients died. ECS of metastatic LNs was not correlated with survival although the follow-up period was relatively short to evaluate survival rate accurately.

In conclusion, ECS of metastatic LNs in PTC is an important prognostic factor for loco-regional recurrence.

**DISCUSSION**

Rates of cervical LN metastasis in PTC vary. The frequency of cervical LN metastasis was reported to be 20%–41% as detected clinically by preoperative physical examination, US or CT, whereas pathologically confirmed cervical LN metastasis occurred in 20%–80% of cases [7-10]. In this study, 22.4% of the patients (75/335) had clinically detectable LN metastasis by physical examination or imaging study while 60.0% (201/335) had LN metastasis confirmed pathologically after surgery. According to several studies, cervical LN metastasis is related to lower age, large tumor size, presence of ETE, and positive BRAF V600E mutation [11-13]. In this study, lower age, male gender, and large tumor size were associated with increased cervical LN metastasis.

Cervical LN metastasis in differentiated thyroid carcinoma has no definite effect on prognosis, but is a critical factor for local recurrence [14]. In this study, young age, ETE, lateral LN metastasis, and ECS of metastatic LNs were significantly related to loco-regional recurrence.

The size and number of metastatic LNs is thought to be associated with local recurrence although this is controversial [11,15,16]. In this study, the size of metastatic LNs was not significantly correlated with loco-regional recurrence.

Several studies have concluded that ECS of metastatic LNs is related to lower age, large tumor size, presence of ETE, and size and number of metastatic LNs [11,12,17-21]. T4 tumors and high-risk features according to the American Thyroid Association guidelines were associated with ECS of metastatic LNs [19]. In this study, ECS of metastatic LNs was related to male gender, large tumor size, presence of ETE, large size of metastatic LNs and large size of metastatic foci.

ECS of metastatic LNs is regarded as a poor prognostic factor for local recurrence and survival in some human cancers such as head and neck, breast and bladder cancers. ECS of metastatic LNs, especially in head and neck cancers, is considered an important adverse prognostic factor for local recurrence and distant metastasis, as well as for survival [4,5].

There are differing opinions about the significance of ECS in PTC. Several studies have reported it to be a prognostic indicator for local recurrence, distant metastasis, and decreased survival [11,12,17-21]. A recent paper concluded that the risk of recurrence was 1% in patients with LN metastasis without ECS, 4% in those with three metastatic LNs showing ECS, and 32% in those with more than three metastatic LNs showing ECS [11]. According to another study more than three metastatic LNs showing ECS was also a significant risk factor for persistent disease and recurrent disease [20]. In addition, concurrent BRAF V600E mutation and ECS of metastatic LNs have been shown to predict significantly worse disease free survival [18]. However, in other studies workers found that recurrence was not correlated with ECS of metastatic LNs [22,23].

In our study, ECS of metastatic LNs was significantly associated with loco-regional recurrence. Young age and presence of ECS, in particular, were significantly associated with recurrence among patients with cervical LN metastasis. Therefore, close postoperative surveillance and appropriate adjuvant treatment should be considered in patients with ECS in order to detect early recurrence and minimize loco-regional recurrence. In this study, only two patients died. ECS of metastatic LNs was not correlated with survival although the follow-up period was relatively short to evaluate survival rate accurately.

In conclusion, ECS of metastatic LNs in PTC is an important prognostic factor for loco-regional recurrence.

**CONFLICT OF INTEREST**

No potential conflict of interest relevant to this article was reported.

**REFERENCES**

1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer. 1998 Dec;83(12): 2638-48.
2. Ito Y, Miyauchi A, Kihara M, Takamura Y, Kobayashi K, Miya A. Re-
lationship between prognosis of papillary thyroid carcinoma patient and age: a retrospective single-institution study. Endocr J. 2012; 59(5):399-405.

3. Oyer SL, Smith VA, Lentsch EJ. Reevaluating the prognostic significance of age in differentiated thyroid cancer. Otolaryngol Head Neck Surg. 2012 Aug;147(2):221-6.

4. Johnson JT, Myers EN, Bedetti CD, Barnes EL, Schramm VL Jr, Thearle PB. Cervical lymph node metastases. Incidence and implications of extracapsular carcinoma. Arch Otolaryngol. 1985 Aug;111(8): 534-7.

5. de Juan J, Garcia J, Lopez M, Orus C, Esteller E, Quer M, et al. Inclusion of extracapsular spread in the pTNM classification system: a proposal for patients with head and neck carcinoma. JAMA Otolaryngol Head Neck Surg. 2013 May;139(5):483-8.

6. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.

7. Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorin MB, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002 Aug;26(8):879-85.

8. Shaha AR, Shah JP, Loree TR. Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid. Am J Surg. 1996 Dec;172(6):692-4.

9. Lee DW, Ji YB, Sung ES, Park JS, Lee YJ, Park DW, et al. Roles of ultrasonography and computed tomography in the surgical management of cervical lymph node metastases in papillary thyroid carcinoma. Eur J Surg Oncol. 2013 Feb;39(2):191-6.

10. Ji YB, Lee KJ, Park YS, Hong SM, Paik SS, Tae K. Clinical efficacy of sentinel lymph node biopsy using methylene blue dye in clinically node-negative papillary thyroid carcinoma. Ann Surg Oncol. 2012 Jun;19(6):1868-73.

11. Randolph GW, Dahi QY, Heller KS, LiVolsi VA, Mandel SJ, Steward DL, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid. 2012 Nov;22(11):1144-52.

12. Yamashita H, Noguchi S, Murakami N, Kawamoto H, Watanabe S. Extracapsular invasion of lymph node metastases is an indicator of distant metastasis and poor prognosis in patients with thyroid papillary carcinoma. Cancer. 1997 Dec;80(12):2268-72.

13. Joo JY, Park JY, Yoon YH, Choi B, Kim JM, Jo YS, et al. Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study. J Clin Endocrinol Metab. 2012 Nov;97(11): 3996-4003.